To study the immune basis of COVID-19 related acute respiratory distress syndrome (ARDs) via longitudinal study of patients undergoing placebo and convalescent plasma treatment in order to inform evidence-based repurposing of targeted immunotherapies to improve outcomes for critically-ill patients affected by COVID-19.

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Emergent Ventures Fast Grants
  • Principal Investigator

    Dr. Jeff Biernaskie
  • Research Location

    Canada
  • Lead Research Institution

    University of Calgary
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Controlled Clinical Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

To study the immune basis of COVID-19 related acute respiratory distress syndrome (ARDs) via longitudinal study of patients undergoing placebo and convalescent plasma treatment in order to inform evidence-based repurposing of targeted immunotherapies to improve outcomes for critically-ill patients affected by COVID-19.